No matches
Dermatology

Bullous Pemphigoid Is an Autoimmune Disease Involving Dysregulated Type 2 Immune Response

Listen as Dr. Donna Culton discusses the importance of crosstalk between autoantibodies and type 2 inflammation in the development of bullous pemphigoid.
Donna Aline Culton
MD, PhD
Donna Aline Culton

Related resources

Explore the clinical presentations of bullous pemphigoid (BP), the steps for diagnosis, and the burden of disease.

Bullous Pemphigoid (BP): Don't Miss the Diagnosis

Infographic
Navigating Atopic Dermatitis and Hand and Foot Dermatitis: Clinical Manifestations and Pathophysiology

Navigating Atopic Dermatitis and Hand and Foot Dermatitis: Clinical Manifestations and Pathophysiology

expert video
Disease Modification Concepts in AD

Disease Modification Concepts in AD

expert video
Barrier disruption in AD and the development of environmental and food allergies

Barrier disruption in AD and the development of environmental and food allergies

expert video
Bullous Pemphigoid Mechanism of Disease Video

Bullous Pemphigoid Mechanism of Disease Video

videoanimation
Diagnosis of Bullous Pemphigoid Interactive Patient Case

Diagnosis of Bullous Pemphigoid Interactive Patient Case

interactivity
What do we mean by disease control in AD?

What do we mean by disease control in AD?

expert video
The Patient Burden of Chronic Pruritus of Unknown Origin (CPUO)

The Patient Burden of Chronic Pruritus of Unknown Origin (CPUO)

Infographic
Stepping Into Hand and Foot Dermatitis

Stepping Into Hand and Foot Dermatitis

expert video
Understanding Disease Mechanisms

Understanding Disease Mechanisms

expert video
Guideline-Based Diagnosis of Atopic Dermatitis

Guideline-Based Diagnosis of Atopic Dermatitis

interactivity
Etiology and Diagnosis of Bullous Pemphigoid

Etiology and Diagnosis of Bullous Pemphigoid

expert video
Pathophysiology of Blister Formation in Bullous Pemphigoid

Pathophysiology of Blister Formation in Bullous Pemphigoid

expert video
Unmet Needs for Bullous Pemphigoid (BP): Limitations of Diagnosis and Conventional Therapies

Unmet Needs for Bullous Pemphigoid (BP): Limitations of Diagnosis and Conventional Therapies

expert video
What We Know About Bullous Pemphigoid (BP): Challenges of the Various Clinical Manifestations, Diagnosis, and Burden for Patients and Caregiver

What We Know About Bullous Pemphigoid (BP): Challenges of the Various Clinical Manifestations, Diagnosis, and Burden for Patients and Caregivers

expert video
Mechanisms of Disease: Autoimmunity and Role of Type 2 Inflammation in BP

Mechanisms of Disease: Autoimmunity and Role of Type 2 Inflammation in Bullous Pemphigoid (BP)

expert video
Factors Contributing to Diagnostic Delays in Bullous Pemphigoid

Factors Contributing to Diagnostic Delays in Bullous Pemphigoid

expert video
Scratching the Surface: Understanding Itch in Prurigo Nodularis

Scratching the Surface: Understanding Itch in Prurigo Nodularis

expert video
What Drives Chronic Itch and the Itch-Scratch Cycle in Atopic Dermatitis?

What Drives Chronic Itch and the Itch-Scratch Cycle in Atopic Dermatitis?

videoanimation
Unveiling Atopic Dermatitis

Unveiling Atopic Dermatitis

expert video
Identification and Management of AD Uncontrolled With Topical Therapies in Children

Identification and Management of AD Uncontrolled With Topical Therapies in Children

expert video
Epidemiology and Pathophysiology of AD in Children

Epidemiology and Pathophysiology of AD in Children

expert video
Key Treatment Considerations for Management of Atopic Dermatitis in Children

Key Treatment Considerations for Management of Atopic Dermatitis in Children

expert video
Role of Type 2 Inflammation in Skin Barrier Disruption and Itch

Role of Type 2 Inflammation in Skin Barrier Disruption and Itch

expert video
ADVENT On Air | Exploring The Urgency to Treat in Atopic Dermatitis

ADVENT On Air | Exploring The Urgency to Treat in Atopic Dermatitis

Podcast
Chronic Spontaneous Urticaria Mechanism of Disease Animation

Chronic Spontaneous Urticaria Mechanism of Disease Animation

videoanimation
Pathophysiology of Bullous Pemphigoid

Pathophysiology of Bullous Pemphigoid

expert video
Diagnosis and Clinical Manifestations of Bullous Pemphigoid

Diagnosis and Clinical Manifestations of Bullous Pemphigoid

expert video
Unmet Needs in Bullous Pemphigoid

Unmet Needs in Bullous Pemphigoid

expert video
Heterogeneous Clinical Presentations and Diagnostic Challenges With Bullous Pemphigoid (BP)

Heterogeneous Clinical Presentations and Diagnostic Challenges With Bullous Pemphigoid (BP)

expert video
Unmet Needs and Management Challenges in Bullous Pemphigoid (BP)

Unmet Needs and Management Challenges in Bullous Pemphigoid (BP)

expert video
Under the Skin: Autoimmunity and Type 2 Inflammation in Bullous Pemphigoid (BP)

Under the Skin: Autoimmunity and Type 2 Inflammation in Bullous Pemphigoid (BP)

expert video
CSU is Associated With a High Burden and Impact on Quality of Life

CSU is Associated With a High Burden and Impact on Quality of Life

expert video
Inside the Hive: ​Type 2 Inflammatory Pathways in Chronic Spontaneous Urticaria

Inside the Hive: ​Type 2 Inflammatory Pathways in Chronic Spontaneous Urticaria

expert video
Blisters and Beyond: Autoimmunity Meets Type 2 Inflammation in Bullous Pemphigoid

Blisters and Beyond: Autoimmunity Meets Type 2 Inflammation in Bullous Pemphigoid

expert video
What Went Wrong? How Dysregulated Type 2 Immunity Contributes to AD, PN, CSU, and BP

What Went Wrong? How Dysregulated Type 2 Immunity Contributes to AD, PN, CSU, and BP

expert video
How Does Protective Type 2 Immunity Become Harmful Type 2 Inflammation?

How Does Protective Type 2 Immunity Become Harmful Type 2 Inflammation?

expert video
Under the Itchy Surface: The Insidious, Cumulative Burden of Type 2 Inflammation in AD

Under the Itchy Surface: The Insidious, Cumulative Burden of Type 2 Inflammation in AD

expert video
How Does Protective Type 2 Immunity Become Harmful Type 2 Inflammation?

How Does Protective Type 2 Immunity Become Harmful Type 2 Inflammation?

expert video
The Clinical Presentation of CSU is Heterogeneous

The Clinical Presentation of CSU is Heterogeneous

expert video
Under the Itchy Surface: The Insidious, Cumulative Burden of Type 2 Inflammation in AD

Under the Itchy Surface: The Insidious, Cumulative Burden of Type 2 Inflammation in AD

expert video
The Role of Type 2 Inflammation in Multiple Disease Trajectories

The Role of Type 2 Inflammation in Multiple Disease Trajectories

Infographic
KOL Video Interview – Dr. Eric Simpson

KOL Video Interview – Dr. Eric Simpson

expert video
Persistence of AD From Childhood Into Adulthood

Persistence of AD From Childhood Into Adulthood

expert video
Identifying BP: How do symptoms of BP and their severity alter patient diagnosis?

Identifying BP: How do symptoms of BP and their severity alter patient diagnosis?

expert video
Considerations for Disease Modification in AD

Considerations for Disease Modification in AD

expert video
IL-4 Contributes to Systemic Type 2 Inflammation in AD

IL-4 Contributes to Systemic Type 2 Inflammation in AD

expert video
What Went Wrong? How Dysregulated Type 2 Immunity Contributes to AD, PN, CSU, and BP

What Went Wrong? How Dysregulated Type 2 Immunity Contributes to AD, PN, CSU, and BP

slide presentation
KOL Video Interview – Dr Amy Paller

KOL Video Interview – Dr Amy Paller

expert video

Learning objectives

  • Explore the role of both autoantibodies and type 2 inflammation in bullous pemphigoid pathophysiology
Tags
IL-4IL-13chronic inflammationPathophysiologytype 2 inflammationBullous Pemphigoid
MAT-US-2606823 v1.0- P Expiration Date: 06/09/2028

About this expert

Dermatology

Donna Aline Culton

MD, PhD

Professor of Dermatology Associate Director, Clinical Trials Unit Director, Clinical Immunofluorescence Laboratory  University of North Carolina, Chapel Hill Chapel Hill, NC, USA

See author’s profile
Donna Aline Culton

ADVENT is a global medical education non-promotional program by Sanofi and Regeneron. This website is intended only for duly authenticated healthcare professionals in Algeria, Argentina, Australia, Austria, Bahrain, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Dominican Republic, Ecuador, Egypt, Estonia, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Iceland, India, Israel, Italy, Japan, Kuwait, Latvia, Lebanon, Lithuania, Macau, Malaysia, Norway, Oman, Panama, Peru, Poland, Portugal, Qatar, Romania, Saudi Arabia, Singapore, Slovenia, South Africa, South Korea, Spain, Sudan, Sweden, Switzerland, Taiwan, Thailand, The Netherlands, Turkey, United Arab Emirates, or the United States of America.

For healthcare professionals in Algeria: Please read the additional Terms of Use.

Sanofi | Regeneron Logo

© 2026 Sanofi and Regeneron Pharmaceuticals, Inc.

All rights reserved.
MAT-US-2305040 v4.0 – P Expiration Date: 10/16/2027

All Rights Reserved.

Sanofi and Regeneron are global leaders in pharmaceutical development, each with a long history of supporting frontline physicians to improve human health and reduce the burden of disease. Driven by the same commitment to patients and their families, Sanofi and Regeneron have partnered to take on type 2 inflammation and the range of chronic conditions in which excessive inflammation plays a role.

Country/region: United StatesChange country/region